PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
Chemistry at the Core
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
Built for Patients
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
Driven by Purpose
We are passionate about using our expertise to address the needs of patients with cancer.
John Soglia, PhD
Translational Development
John Soglia, PhD
Translational Development
Amit Deshpande, PhD
Translational Medicine
Amit Deshpande, PhD
Translational Medicine
Ruth Adams
Clinical Operations
Ruth Adams
Clinical Operations
James Porter, PhD
Chief Executive Officer
James Porter, PhD
Chief Executive Officer
Joshua Horan, PhD
Chemistry
Joshua Horan, PhD
Chemistry
Scot Mente, PhD
Computational Chemistry
Scot Mente, PhD
Computational Chemistry
Jason Kropp
Pharmaceutical Development
Jason Kropp
Pharmaceutical Development
Darlene Noci, ALM
Product Development & Regulatory Affairs
Darlene Noci, ALM
Product Development & Regulatory Affairs
Kristin Andrews, PhD
Computational Chemistry
Kristin Andrews, PhD
Computational Chemistry
Henry Pelish, PhD
Biology
Henry Pelish, PhD
Biology
Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer
Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology
Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology
Matthew Campbell
Pharmaceutical Development
Matthew Campbell
Pharmaceutical Development
Baudouin Gerard, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Medicinal Chemistry
Alex Balcom
Chief Financial Officer
Alex Balcom
Chief Financial Officer
Benjamin Lane, PhD
Pharmaceutical Development
Benjamin Lane, PhD
Pharmaceutical Development
